
03-73-06



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV727274 62545 Express Mail Label Number

ARCH

CASE ON/4-32586A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

OHTSURU ET AL.

INTERNATIONAL APPLICATION NO: PCT/IB03/01985

FILED: 23 MAY 2003

U.S. APPLICATION NO: 10/521,929 35 USC §371 DATE: 5 AUGUST 2005

FOR: 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-

PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE FOF

TREATING ANAPLASTIC THYROID CANCER

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report and since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Attorney for Applicants

Oona A. Jackson

Reg. No. 48,152

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7852

Date: 3/22/00

- 2 -

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. ON/4-32586A APPLICATION NO. 10/521,929 APPLICANT OHTSURU ET AL. FILING DATE AUGUST 5, 2005

Group

MAR 2 2 2006

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD	"		· · · · · · · · · ·			
	AE						
	AF						
· <u>-</u>	AG						
	АН						
	AI						_
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
AM	* WO 99/03854	01/28/99	WIPO				
AN	* EP 0 564 409 [in German; English claims equivalent in AU-B-35694/93]	10/06/93	Europe				
AO	* AU-B-35694/93 [English claims corresponding to EP 0 546 409]	10/07/93	Australia				
AP							
AQ							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

АТ	Eng, "Biology of Neoplasia. RET Proto-Oncogene in the Development of Human Cancer", J Clin Oncol, Vol. 17, No. 1, pp. 380-393 (1999).
 AS	by Tyrosine Kinase Inhibitors", Surgery, Vol. 132, No. 6, pp. 960-968 (2002).
	* Cohen et al., "Inhibition of Medullary Thyroid Carcinoma Cell Proliferation and RET Phosphorylation
AR	Cohen, Residence in General Surgery, Homepage of the Washington University School of Medicine, Dept. of Surgery (1997, 1998).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. ON/4-32586A APPLICATION NO. 10/521,929 APPLICANT OHTSURU ET AL. FILING DATE AUGUST 5, 2005

Group

EXAMINER INITIAL	ОТН	ER DOCUMENTS (Including Author, Titl	e, Date, Pertinent pages, Etc.)
	DA	into Pathogenesis and Tumor-specific pp. 2025-2028 (2002).	I from Molecular Genetic Studies of Thyroid Cancer–Insights Therapeutic Targets", <i>Endocrinology</i> , Vol. 143, No. 6,
	DB	Hepatocyte Growth Factor", Oncogen	or STI571 Enhances Thyroid Cancer Cell Motile Response to e, Vol. 20, No. 29, pp. 3845-3856 (2001).
	DC	* Joensuu and Dimitrijevic, "Tyrosine Solid Tumours", <i>Ann Med</i> , Vol. 33, No	Kinase Inhibitor Imatinib (STI571) as an Anticancer Agent for b. 7, pp. 451-455 (2001).
	DD		"Multiple Endocrine Neoplasia Type 2 Syndromes May be , J Intern Med, Vol. 250, No. 1, pp. 37-42 (2001).
	DE	Meric et al., "Expression Profile of Tyr No. 2, pp. 361-367 (2002).	osine Kinases in Breast Cancer", Clin Cancer Res, Vol. 8,
	DF	* Podtcheko et al., "The Selective Tyre Thyroid Cancer Cells", <i>J Clin Endocri</i>	osine Kinase Inhibitor, STI571, Inhibits Growth of Anaplastic nol Metab, Vol. 88, No. 4, pp. 1889-1896 (2003).
	DG		
	DH		
	DI		
	DJ		
	DK		
	DL		
	DM		
	DN		
EXAMINER	?		DATE CONSIDERED

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.